Huyabio International and BMS to collaborate on melanoma clinical

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Huyabio International and Bristol-Myers Squibb Co. are planning to evaluate the combination of Huyabio’s HBI-8000, an epigenetic immunomodifier, and Opdivo (nivolumab), a PD-1 blocking antibody.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login